Bronchodilator Drugs - Southeast Asia

Southeast Asia

The Bronchodilator Drugs market in Southeast Asia is predicted to witness a significant increase in revenue, with projections indicating that it will reach US$0.35bn by 2024.
Furthermore, it is expected to maintain a steady annual growth rate (CAGR 2024-2028) of 4.03%, leading to a market volume of US$0.41bn by 2028.
When compared to other countries, United States is anticipated to generate the highest revenue in the global Bronchodilator Drugs market, amounting to US$17,340.00m in 2024.
In Southeast Asia, there is a growing demand for bronchodilator drugs due to the high prevalence of respiratory diseases in the region.

Key regions: Europe, India, Canada, Italy, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

Bronchodilator drugs are used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The market for these drugs in Southeast Asia has been steadily growing in recent years.

Customer preferences: Customers in Southeast Asia are increasingly looking for affordable and effective medication to treat respiratory diseases. With the rise of air pollution and smoking in the region, the demand for bronchodilator drugs has increased significantly.

Trends in the market: In Indonesia, the market for bronchodilator drugs is expected to grow due to the country's high prevalence of respiratory diseases. The government's efforts to improve healthcare infrastructure and increase access to medication have also contributed to the growth of the market.In the Philippines, the market for bronchodilator drugs is driven by the country's high smoking rates and poor air quality. The rise of chronic respiratory diseases in the country has also contributed to the growth of the market.In Thailand, the market for bronchodilator drugs is expected to grow due to the country's aging population and the high prevalence of respiratory diseases. The government's efforts to improve healthcare infrastructure and increase access to medication have also contributed to the growth of the market.

Local special circumstances: In Indonesia, the government's universal healthcare program has increased access to medication for the population. However, the country's large rural population and lack of healthcare infrastructure in some areas remain a challenge for the distribution of medication.In the Philippines, the government's efforts to increase access to medication through its PhilHealth program have been hindered by corruption and inefficiencies in the healthcare system. This has resulted in limited access to medication for some of the population.In Thailand, the government's efforts to increase access to medication through its Universal Coverage Scheme have been successful in improving healthcare outcomes. However, the country's aging population and rising healthcare costs remain a challenge for the sustainability of the healthcare system.

Underlying macroeconomic factors: The growth of the market for bronchodilator drugs in Southeast Asia is driven by the region's growing population, rising healthcare spending, and increasing prevalence of respiratory diseases. The region's economic growth and improving healthcare infrastructure have also contributed to the growth of the market.In conclusion, the market for bronchodilator drugs in Southeast Asia is expected to continue growing in the coming years due to the region's high prevalence of respiratory diseases and increasing demand for affordable and effective medication. However, challenges such as limited healthcare infrastructure and rising healthcare costs remain a concern for the sustainability of the healthcare system in the region.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.